Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alexandra Lelchuk

Interventional Pain Medicine Kenosha, WI Medical Doctor

NPI 1336594910 CMS profile 8801846

6815 118Th Ave, Kenosha, WI 53142

Open in the dashboard

General payments

$9,259

52 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Lelchuk of Kenosha, WI is reported in the CMS Open Payments database as having received $9,259 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81 3
2024 General $227 6
2023 General $408 13
2022 General $2,146 14
2021 General $1,306 13
2020 General $5,091 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Lelchuk
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Alexandra Lelchuk were reported at $81. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Alexandra Lelchuk Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $5,091 $382 $122–$1,109 $114
2021 $1,306 $552 $167–$1,554 $132
2022 $2,146 $605 $187–$1,924 $149
2023 $408 $671 $195–$1,915 $160
2024 $227 $684 $206–$1,837 $164
2025 $81 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic USA, Inc. $5,091 3 payments
  2. Medtronic, Inc. $2,338 28 payments
  3. Abbott Laboratories $756 8 payments
  4. Boston Scientific Corporation $704 8 payments
  5. SPR Therapeutics, Inc $275 3 payments
  6. Baudax Bio Inc. $64 1 payment
  7. Pacira Pharmaceuticals Incorporated $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $5,000 1 payment
  2. Food and Beverage $2,839 45 payments
  3. Travel and Lodging $1,419 6 payments
Products named General payments · program years 2020–2025
  1. INTELLIS Spinal Cord Neurostimulation $5,000 1 payment
  2. INTELLIS ADAPTIVESTIM $1,719 20 payments
  3. SYNCHROMED $426 5 payments
  4. WAVEWRITER ALPHA $293 2 payments
  5. SPRINT PNS System $275 3 payments
  6. General - Therapies $220 1 payment
  7. IonicRF Generator $198 1 payment
  8. Proclaim IPG $171 2 payments
  9. AXIUM $155 1 payment
  10. INTELLIS Spinal Cord Neurostimulation $154 2 payments
  11. Other $619 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

729

Median for Interventional Pain Management: 1,220

Drug cost

$21,673

Median for Interventional Pain Management: $39,344

Branded share of claims

3.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Savella Milnacipran Hcl Brand 11 $10,900
Lidocaine Generic 31 $2,701
Gabapentin Generic 158 $2,562
Pregabalin Generic 84 $1,401
Baclofen Generic 134 $1,332
Diclofenac Sodium Generic 11 $1,115
Cyclobenzaprine Hcl Generic 82 $609
Tizanidine Hcl Generic 73 $378
Duloxetine Hcl Generic 39 $255
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $207

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$44,410

Medicare's payments for the services billed

Medicare patients

140

Average age 73

Services billed

806

93 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 35%
Diabetes 34%
Depression 29%
Ischemic heart disease 23%
COPD 23%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record